Full metadata record

DC Field Value Language
dc.contributor.authorJo, Hyoung-
dc.contributor.authorJung, Sang Hoon-
dc.contributor.authorKang, Jun-
dc.contributor.authorYim, Hye Bin-
dc.contributor.authorKang, Kui Dong-
dc.date.accessioned2024-01-20T08:31:02Z-
dc.date.available2024-01-20T08:31:02Z-
dc.date.created2021-09-02-
dc.date.issued2014-11-30-
dc.identifier.issn1976-6696-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/126091-
dc.description.abstractSulodexide is a mixed glycosaminoglycan composed of heparin and dermatan sulfate. In this study, the anti-angiogenic effect of sulodexide was investigated using an oxygen-induced retinopathy (OIR) mouse model. The retinas of sham-injected OIR mice (P17) had a distinctive central area of nonperfusion, and this area was significantly decreased in sulodexide-injected mice. The number of neovascular tufts measured by SWIFT_ NV and mean neovascular lumen number were significantly decreased in sulodexide-injected mice. Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. Our results clearly demonstrate the anti-angiogenic effect of sulodexide and highlight sulodexide as a candidate supplementary substance to be used for the treatment of ocular pathologies that involve neovascularization.-
dc.languageEnglish-
dc.publisherKOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY-
dc.subjectENDOTHELIAL GROWTH-FACTOR-
dc.subjectRETRO-ORBITAL INJECTION-
dc.subjectDIABETIC-NEPHROPATHY-
dc.subjectFACTOR VEGF-
dc.subjectRECEPTOR-
dc.subjectCELLS-
dc.subjectANGIOGENESIS-
dc.subjectPREMATURITY-
dc.subjectEXPRESSION-
dc.titleSulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy-
dc.typeArticle-
dc.identifier.doi10.5483/BMBRep.2014.47.11.009-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBMB REPORTS, v.47, no.11, pp.637 - 642-
dc.citation.titleBMB REPORTS-
dc.citation.volume47-
dc.citation.number11-
dc.citation.startPage637-
dc.citation.endPage642-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
dc.identifier.wosid000345347400006-
dc.identifier.scopusid2-s2.0-84914814617-
dc.relation.journalWebOfScienceCategoryBiochemistry & Molecular Biology-
dc.relation.journalResearchAreaBiochemistry & Molecular Biology-
dc.type.docTypeArticle-
dc.subject.keywordPlusENDOTHELIAL GROWTH-FACTOR-
dc.subject.keywordPlusRETRO-ORBITAL INJECTION-
dc.subject.keywordPlusDIABETIC-NEPHROPATHY-
dc.subject.keywordPlusFACTOR VEGF-
dc.subject.keywordPlusRECEPTOR-
dc.subject.keywordPlusCELLS-
dc.subject.keywordPlusANGIOGENESIS-
dc.subject.keywordPlusPREMATURITY-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordAuthorAngiogenesis-
dc.subject.keywordAuthorMMP-
dc.subject.keywordAuthorRetinopathy-
dc.subject.keywordAuthorSulodexide-
dc.subject.keywordAuthorVEGF-
Appears in Collections:
KIST Article > 2014
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE